The FDA approved Vizz for the treatment of presbyopia in adults, according to a press release from Lenz Therapeutics.
Once-daily Vizz (aceclidine ophthalmic solution 1.44%) contracts the iris sphincter muscle, creating a pinhole effect to extend depth of focus and improve near vision without a myopic shift, according to the release.
“Vizz is a convenient, once-daily solution that improves consumers’ near visual experience, allowing them to stay in the moment,” Eef Schimmelpennink, president
and CEO of Lenz Therapeutics, told PCON in an email. “Vizz provides another option